ALNY Alnylam Pharmaceuticals, Inc.
Healthcare$296.45+0.00%OpenMarket Cap: $39.58B
As of 2026-05-26
Analyst Consensus
Consensus
Buy
Target (Consensus)
$445.67
Target (Median)
$445.50
Target Range
$351.00 - $530.00
Upside from current price: 50.3%
Rating Distribution
7 Strong Buy15 Buy8 Hold0 Sell0 Strong Sell
Recent Analyst Ratings
| Date | Firm | Action | Rating | Previous |
|---|---|---|---|---|
| 2026-05-05 | HC Wainwright & Co. | maintain | Buy | Buy |
| 2026-05-01 | RBC Capital | maintain | Outperform | Outperform |
| 2026-05-01 | Wells Fargo | maintain | Equal Weight | Equal Weight |
| 2026-04-13 | Truist Securities | maintain | Buy | Buy |
| 2026-03-25 | HC Wainwright & Co. | maintain | Buy | Buy |
| 2026-03-25 | Chardan Capital | maintain | Buy | Buy |
| 2026-03-16 | Jefferies | downgrade | Hold | Buy |
| 2026-02-18 | HC Wainwright & Co. | maintain | Buy | Buy |
| 2026-02-17 | Freedom Broker | upgrade | Buy | Hold |
| 2026-02-17 | Canaccord Genuity | maintain | Buy | Buy |
Forward Estimates
| Period | EPS Est. | Revenue Est. | # Analysts |
|---|---|---|---|
| Fri Dec 31 | $10.67 | $7.33B | 15 |
| Sun Dec 31 | $13.19 | $8.71B | 16 |
| Mon Dec 31 | $15.81 | $10.16B | 14 |
| Tue Dec 31 | $19.43 | $11.74B | 14 |